NeurogesX reports second quarter 2012 results (Globenewswire) - Aug 3, 2012 - NeurogesX seeking partner in US and and other world markets for NGX-1998 and Qutenza; NGX-1998 P3 study expected by end of the year
Anticipated licensing / partnership • Anticipated new P3 trial • Pain
|
|
Astellas is expanding their commercialization of Qutenza across the EU and into additional countries and markets. Astellas is a best-in-class commercial and development organization, and their expertise is creating value with Qutenza. Astellas' dedication to the program is exemplified by their clinical development program, which includes a Phase 3 trial of Qutenza in painful diabetic peripheral neuropathy and Phase 4 studies."
Ronald Martell, President and CEO, stated, "Our efforts to secure a development and commercialization partner for NGX-1998 and Qutenza in the United States and other world markets remain a high priority for us. Advancing the development of our next generation, prescription-strength capsaicin product candidate NGX-1998 is our continued focus as we make progress towards enabling a Phase 3 trial by the end of the year
|